Valuation: HLB Life Science Co., Ltd.

Capitalization 1,219B 847M 807M 761M 672M 1.2B 73.4B 1.33B 9.06B 3.36B 30.69B 3.18B 3.11B 129B P/E ratio 2022
-19.7x
P/E ratio 2023 -195x
Enterprise value 1,307B 908M 865M 816M 720M 1.29B 78.68B 1.43B 9.71B 3.6B 32.9B 3.4B 3.34B 138B EV / Sales 2022
11x
EV / Sales 2023 12.8x
Free-Float
-
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
HLB bioStep Co.,Ltd. announced that it expects to receive KRW 20 billion in funding from Heyman Co., Ltd., Oruminc.Co.,Ltd, HLB Genex, Inc., HLB Life Science Co., Ltd. and other investors Feb. 11 CI
HLB Life Science Co., Ltd. announced that it has received KRW 5 billion in funding Jan. 09 CI
HLB Life Science Co., Ltd. announced that it expects to receive KRW 5 billion in funding Jan. 07 CI
GenoFocus, Inc. announced that it has received KRW 69.999981686 billion in funding from a group of investors Dec. 11 CI
HLB Life Science Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 14 CI
GenoFocus, Inc. announced that it expects to receive KRW 69.999981686 billion in funding from a group of investors 24-10-27 CI
HLB SCIENCE Inc. announced that it has received KRW 2.999998812 billion in funding from HLB Life Science Co., Ltd. 24-10-09 CI
HLB SCIENCE Inc. announced that it expects to receive KRW 2.999998812 billion in funding from HLB Life Science Co., Ltd. 24-09-23 CI
HLB Life Science Co., Ltd. announced that it expects to receive KRW 2.999998812 billion in funding 24-09-23 CI
HLB Life Science Co., Ltd. announced that it has received KRW 50 billion in funding from Korea Investment & Securities Co., Ltd., KB Securities Co.,Ltd, JJ Assets Co., Ltd., DnSI Holdings Co.,Ltd., Kukdong Corporation, Creas F&C Co.,Ltd and other investors 24-08-28 CI
HLB Life Science Co., Ltd. announced that it expects to receive KRW 50 billion in funding from Korea Investment & Securities Co., Ltd., KB Securities Co.,Ltd, JJ Assets Co., Ltd., DnSI Holdings Co.,Ltd., Kukdong Corporation, Creas F&C Co.,Ltd and other investors 24-08-20 CI
HLB Life Science Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 24-08-14 CI
HLB Life Science Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 24-05-13 CI
More news
1 day-1.59%
1 week-2.07%
Current month-6.77%
1 month-7.64%
3 months+22.02%
6 months-9.57%
Current year-0.90%
More quotes
1 week
9 860.00
Extreme 9860
10 270.00
1 month
9 860.00
Extreme 9860
11 740.00
Current year
9 860.00
Extreme 9860
11 740.00
1 year
7 700.00
Extreme 7700
25 000.00
3 years
7 700.00
Extreme 7700
25 000.00
5 years
6 893.61
Extreme 6893.612
25 000.00
10 years
729.77
Extreme 729.772
25 000.00
More quotes
Director TitleAgeSince
Chief Executive Officer 67 -
Chief Executive Officer 59 2019-06-24
Chief Tech/Sci/R&D Officer 55 -
Manager TitleAgeSince
Chairman 59 -
Director/Board Member 67 -
Director/Board Member 49 -
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-1.59%-2.07%-39.59%-1.11% 908M
-1.46%-0.34%+17.40%+116.75% 74.41B
-0.45%-0.91%+20.27%+135.77% 30.49B
+0.80%-0.54%+14.77%+6.04% 9.21B
+0.64%-0.83%+9.28%-4.52% 8.3B
+2.26%0.00%-3.77%+3.64% 7.99B
-3.23%-0.57%+26.33% - 5.62B
-0.95%+0.97%+14.68%+6.09% 4.66B
+0.25%0.00%+7.07%+26.33% 4.54B
+1.99%+2.40%-19.06%+0.35% 3.47B
Average -0.17%-0.25%+4.74%+32.15% 14.96B
Weighted average by Cap. -0.72%-0.37%+14.99%+90.45%
See all sector performances

Financials

2022 2023
Net sales 99.59B 69.2M 65.88M 62.14M 54.88M 98.05M 6B 109M 740M 274M 2.51B 259M 254M 10.52B 97.99B 68.09M 64.82M 61.14M 54M 96.47M 5.9B 107M 728M 270M 2.47B 255M 250M 10.35B
Net income -54.28B -37.72M -35.91M -33.86M -29.91M -53.44M -3.27B -59.3M -403M -149M -1.37B -141M -139M -5.74B -5.98B -4.16M -3.96M -3.73M -3.3M -5.89M -360M -6.54M -44.45M -16.47M -151M -15.59M -15.27M -632M
Net Debt 16.03B 11.14M 10.61M 10M 8.83M 15.78M 965M 17.52M 119M 44.13M 404M 41.76M 40.92M 1.69B 87.72B 60.95M 58.03M 54.73M 48.34M 86.36M 5.28B 95.83M 652M 241M 2.21B 228M 224M 9.27B
More financial data * Estimated data
Logo HLB Life Science Co., Ltd.
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
Employees
145
More about the company
Date Price Change Volume
25-02-14 10,730.00 +8.17% 1,646,140
25-02-13 9,920.00 -1.59% 358,227
25-02-12 10,080.00 +0.60% 168,347
25-02-11 10,020.00 -0.20% 230,095
25-02-10 10,040.00 -1.08% 289,903

End-of-day quote Korea S.E., February 12, 2025

More quotes
  1. Stock Market
  2. Equities
  3. A067630 Stock